STOCKHOLM, Sweden, 6th March 2024 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces that 100 Emollivet shares, corresponding to approximately SEK 0.7 million, have been divested to Cerbios-Pharma SA. As previously announced, Lipidor is carrying out a step-by-step divestment of its holding in the animal company Emollivet AB. A total of […]
STOCKHOLM, Sweden, 20th December 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company, through its partner Cliantha Research, has submitted an application to the Indian Medical Products Agency to start a Phase III study with the drug candidate AKP02G2. The main purpose of the study is to compare […]
STOCKHOLM, den 20 december 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att bolaget genom sin samarbetspartner Cliantha Research har lämnat in en ansökan till indiska läkemedelsmyndigheten om att få starta en Fas III-studie med läkemedelskandidaten AKP02G2. Studiens främsta syfte är att jämföra den terapeutiska effekten hos AKP02G2 med Enstilar […]
STOCKHOLM, Sweden, 22nd November 2023 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its interim report for the period January – September 2023. The report is available on the company's website lipidor.se and in the attached pdf. To read the quarterly report (in Swedish) click here: https://lipidor.se/investors/financial-reports/ Summary of interim report […]
STOCKHOLM, den 22 november 2023 – Idag publicerar Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) sin delårsrapport för perioden januari – september 2023. Kvartalsrapporten finns att hämta på bolagets hemsida lipidor.se samt i form av bifogad pdf. För att läsa kvartalsrapporten för Q3 2023 klicka här: https://lipidor.se/investerare/finansiella-rapporter/ Sammanfattning av delårsrapporten Lipidor arbetar i […]
STOCKHOLM, Sweden, 27th October 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that the company has filed a new patent application with the European Patent Office (EPO). The patent originates from the development that took place during the reformulation work with AKP02, now AKP02G2. In line with Lipidor's strategy, the […]
STOCKHOLM den 27 oktober 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att bolaget har lämnat in en ny patentansökan till den europeiska patentmyndigheten (European Patent Office, EPO). Patentet är sprunget ur den utveckling som skett under omformuleringsarbetet med AKP02, numera AKP02G2. I linje med Lipidors strategi ser bolaget kontinuerligt […]
STOCKHOLM, Sverige, 18 oktober 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) meddelar idag att en ny överenskommelse träffats med RELIFE S.r.l. avseende bolagets psoriasisprojekt. De nya villkoren avser geografisk expansion genom tillägg av Asia-Pacific regionen samt en uppdaterad tidslinje. Lipidor har sedan tidigare tecknat ett licensavtal i vilket Lipidor ger RELIFE […]
STOCKHOLM, Sweden, 18th October 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that a new agreement has been reached with RELIFE S.r.l. regarding the company's psoriasis project. The new terms relate to geographic expansion through the addition of the Asia-Pacific region and an updated timeline. Lipidor has previously signed a […]
STOCKHOLM, Sweden, 20th September 2023 – Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) has signed an agreement with Cliantha Research to conduct a phase III study with the drug candidate AKP02G2, for the treatment of psoriasis. The study is expected to begin recruitment of patients in the first half of 2024 and Lipidor […]